The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression of his/her gut microflora to prevent infections and acute GVHD. Engraftment, GVHD, relapse in the case of malignancy and survival were studied retrospectively in 126 evaluable children, transplanted between 1988 and 2005. In addition to the effect of HLAmatching, that of other transplant-relevant variables on the outcome was also studied. Actuarial OS was 65% and the EFS was 59%, 13% graft failures occurred and 7.5% Xgrade II acute GVHD. HLA-class II mismatches combined with HLA-class I matches resulted in a superior OS of 92%, as did a negative vs positive CTLp test, that is, 65 vs 33%. Analysis of other variables showed a poorer OS in patients X10 yrs vs o10 yrs, that is, 54 vs 73%, and in male recipients of a female donor graft, that is, 53 vs 69% for other combinations. UD-BMT can be optimized by permitting HLA-class I-matched and/or CTLp-negative donors, and probably by choosing male donors for male recipients.
Introduction
Allogeneic haematopoietic SCT is an accepted treatment for a number of inherited and acquired diseases of haematopoiesis in children. [1] [2] [3] [4] Particularly, for diseases for which an alternative treatment is not available or no longer effective, a haematopoietic stem cell donor other than an HLA-matched sibling may be searched for. This is done through the Bone Marrow Donors Worldwide (BMDW) (Europdonor Foundation, Leiden, The Netherlands) database, [5] [6] [7] which includes registries with cord blood units. Several studies have shown that the use of an HLA-matched or partly matched unrelated donor (UD) may be associated with an increased risk of transplantrelated morbidity and mortality. 8, 9 The question thus arises that what is the best UD choice, when no HLA-identical UD is available. SCT using UDs started in 1988 at the Leiden Paediatrics SCT-Centre, using the following policy: (1) a fully HLA-class I-and -class II-matched UD was the first choice and, when not available, an UD matched for HLA-class I and/or with a negative cytotoxic T-lymphocyte precursor (CTLp) test in the graft-vs-host direction was preferred to an HLA-class II-matched UD or other UDs; (2) T cells were left in the graft to enhance engraftment [8] [9] [10] [11] and/or the GVL effect 12 in a number of cases in the situation of either a fully HLA-identical combination, or a negative CTLp test in the graft-vs-host direction in other donor-recipient combinations and (3) all graft recipients were given total gastrointestinal decontamination under strict protective isolation conditions (see further).
In this retrospective study of 133 infants and children, grafted consecutively with UD-BMT over a period of 16 years, the outcome was analysed to determine to what extent our UD selection procedure, based on highresolution HLA typing and functional matching tests, was satisfactory or needs further improvement. Besides HLAmatching criteria, other variables, relevant for the SCT outcome, were also included in the evaluation of the results.
Patients and methods

BM graft recipients
Between June 1988 and January 2005, 445 infants and children received an allogeneic haematopoietic stem cell graft in the Paediatric SCT-Centre of Leiden: 227 of them had an HLA-identical sibling donor; 150 were treated either with a BM graft (n ¼ 133), a PBSC graft (n ¼ 11) or a cord blood graft (n ¼ 6) from an UD; 68 received a BM or a PBSC graft from a haplo-identical parent or other relative. Only the first BMTs with an UD were included in this study. Seven cases were excluded from evaluation because of incomplete HLA-typing data, which could not be recovered (see below). The characteristics of the 126 evaluable cases are given in Table 1 .
Donor-recipient matching and transplant policy Potential donors were searched for in the BMDW database, which contains the broad HLA-phenotypes of about 35 thousand to over 6 million donors in 1989 and 2004, respectively. In the period 1988-1992, donors and recipients were typed for HLA-A, -B, (-C), -DR at split level by serology; a 6/6 or 5/6 matched donor was selected for transplantation. Between 1992 and 1996, donors and recipients were typed for HLA-A, -B, (-C) at split level by serology and for HLA-DRB1 and -DQB1 by highresolution DNA typing. 6 Donors who were 8/8 or 7/8 matched were selected for transplantation with a few exceptions. From 1996 onwards, donors and recipients were typed by DNA typing for HLA-A, -B, -C, -DRB1, -DQB1 (and -DPB1). Donors matched at 10/10 or 9/10 and sometimes 8/10 were selected for transplantation. Recipient-donor pairs for whom high-resolution HLA-typing was not available at the time of transplantation were retyped on frozen material. Seven cases grafted in the earlier period, in which neither material for high-resolution HLA-typing was available nor had a CTLp test been carried out at that time, they were excluded from the evaluation. Only in the case of donors with identically matched grades was matching for HLA-DPB1 taken into account in the selection of a donor.
During the entire period, MLCs were carried out according to Keuning et al. 13 when sufficient material for testing was available. Tests were defined as negative when the relative response value was equal to or o10%. The MLC test was used to determine class II mismatches in the period before class II DNA typing was carried out. In the period thereafter, the MLC test was used to select the donor with the lowest MLC test outcome amongst equally matched donors. From 1992 onwards, the CTLp frequencies in the graft-vs-host direction were determined according to the method described by Kaminski et al.
14 with minor modifications according to Zhang et al. 15 In each test, donor cells were used as responder cells, and recipient cells as stimulator and target cells. A negative CTLp test was defined as p1 CTLp cell per million PBLs.
To evaluate the effect of HLA-matching on the outcome, donor and recipient pairs were classified into several groups, from best fitting to least fitting. Structural matching criteria, that is, identity or dissimilarity of one or more HLA-Ags or alleles in class I and/or class II, were used to categorize BMT-pairs in four groups ( Table 2) : group 1 consisted of A, B, C, DRB1 and DQB1 matched pairs, group 2 of pairs with X1 Ag or allele mismatch in class II, group 3 of pairs with X1 Ag or allele mismatch in class I and group 4 of pairs with X1 Ag or allele mismatch in class I and in class II.
BMT procedure
Variables of possible importance for the evaluation of the results and which concern the transplant procedure are the intensity of pre-treatment and the composition of the graft. Depending on the original diagnosis of the patient and the current protocols of the working parties of the EBMT (European Group for Blood and Marrow Transplantation) or the ESID (European Society for Immune Deficiencies), the recipients were conditioned with a combination of chemotherapy and immunosuppressive antisera, for example, rabbit antithymocyte globulin, or monoclonal antibodies, for example, Campath-1G (TAC, Oxford, UK) or 1H (Bayer, Mijdrecht, The Netherlands) (anti-CD52) or Antilfa (Pasteur-Merieux, Lyon, France) (anti-LFA1, anti CD 11a), and in children above 2 years of age with a haematological malignancy, also with TBI (unfractionated, 7 Gy Â 1, 7.5 Gy Â 1, 8 Gy Â 1 or 6 Gy Â 2, according to age). In the case of a potential risk for GVHD, that is, an HLA-class I mismatch between donor and recipient, T-cell depletion (TCD) of the graft was carried out (n ¼ 60) either by physical means (E-rosetting over a density gradient 16 or immunorosetting 17 ), Campath-1G in the bag 18 or CD34 þ stem cell enrichment by CliniMACS (Miltenyi Biotec, Auburn, CA, USA). 16 GVHD-prophylaxis was according to operative SCT-protocols; it consisted of either MTX- long course (n ¼ 7), MTX-short course plus CsA (n ¼ 78), CsA alone (n ¼ 39) or no drugs in case of vigorous that is, X3 log TCD of the graft, for example, by CliniMACS (n ¼ 2). Besides medical prophylaxis of GVHD, all children were treated in strict protective isolation using a laminar air flow isolator or an ultra-clean room to prevent exogenous infections, 19 and given non-absorbable antimicrobial drugs for non-selective, that is, total suppression of the gastrointestinal tract microflora, until X21 days after BMT, because of its beneficial effect on preventing endogenous bacterial infections and acute GVHD as described earlier. 20 
Variables evaluated
Factors of possible influence on the outcome of the BMT, which were included in this study, are the time period of BMT, the degree of HLA-matching between donor and recipient (see before) 11, [21] [22] [23] [24] [25] and a number of other patientand transplant-related variables, which might have an effect on the outcome of an UD-BMT according to earlier reports. [26] [27] [28] [29] [30] [31] [32] [33] These variables are, besides the original diagnosis and phase of disease in case of malignancy (see Table 1 ), age of donor (o vs X31 yrs) and recipient (o vs X10 yrs), ABO-matching, that is, major incompatibility with recipient's antibodies against donor erythrocytes vs minor or no incompatibility, gender-matching, intensity of pre-treatment, that is, myeloablative (that is, containing either TBI X7 Gy above 2 yrs of age, high-dose BU (X16 mg/kg) or melphalan (X140 mg/m 2 )) vs non-myeloablative, nowadays called reduced intensity, conditioning, that is, containing CY, fludarabine and other immunosuppressive drugs or antibodies, TCD vs no-TCD, number of nucleated cells in the graft, that is, o vs X the median number of 3.30 Â 10 8 /kg body weight of nucleated cells in the BM harvest and serology for CMV of the recipient, that is, negative vs positive. The outcome of the first UD-BMT was evaluated in terms of success or failure of engraftment (that is, non-engraftment or rejection), occurrence of acute and chronic GVHD, relapse in case of BMT for a haematological malignancy, transplant-related mortality, OS and EFS. Patients were considered to be evaluable for engraftment, acute and chronic GVHD when they had survived at least for 21, 50 and 100 days, respectively. With respect to risk for graft failure, patients with BM failure as original disease, that is, children with severe aplastic anaemia and Fanconi anaemia (n ¼ 15), were further categorized as either at increased risk when X20 erythrocyte or thrombocyte transfusions had been given in the preconditioning period or at standard risk. With respect to risk for relapse of the haematological malignancy after BMT, patients transplanted for such a diagnosis (n ¼ 78) were further categorized as at increased risk, that is, myelodysplastic syndromes in transformation or blast crisis, [34] [35] [36] juvenile myelomonocytic leukemia, 37, 38 Ph þ CML longer than 2 years in the first chronic phase or in advanced phase, 39, 40 secondary AML in first complete remission, AML in the second complete remission, 41 ALL in the second complete remission after early BM relapse 42 and ALL in the third complete remission, vs at standard risk (n ¼ 40 vs 38, see Table 1 ).
Statistical analysis
All statistical analyses were carried out in SPSS 12.0 (Amos Development Corp, Chicago, IL, USA). The Pearson w 2 test was used for categorical variables. OS and EFS after transplantation was analysed with Kaplan-Meier curves. For OS, patients were censored at time of death, or at last contact; for EFS they were censored at time of relapse of the malignancy, at time of second transplantation or at time of TRM. Univariate and multivariate analyses were carried out with the Cox Proportional Hazards Model. The evaluation cut-off point was 1 January 2007; all included patients thus had a minimum follow-up of 2 years. During that period all time-related events, except for four late relapses (two Ph þ CML, one myelodysplastic syndrome and one juvenile myelomonocytic leukemia) at 3 and 4 years post-BMT, had occurred. The median follow-up of surviving patients was 7.5 years.
Results Figure 1 shows the actuarial EFS at 2 years of the whole group, that is, 59%, and separately of the patients with a malignant disease and a non-malignant disease, that is, 57 and 63% OS at 2 years was 65% (60 and 73% for malignant and non-malignant diseases, respectively). The actuarial OS and EFS at 5 years was 62 and 55%, respectively, for 94 patients, grafted before 1 January 2002 (data not shown).
In Table 2 , the 126 evaluable cases are classified according to HLA-matching criteria. An MLC test was carried out in 64 donor-recipient couples; test results were to confirm the results of high-resolution HLA-typing (data not shown). A CTLp test was carried out in 64 couples, mostly of groups 1 and 3, and was negative, that is,p1/10 6 , in 55 of them (see Table 2 ). Recipients of an HLA-class Imatched and class II-mismatched donor (group 2) had a superior OS and EFS of 92 and 92%, respectively (see Figure 2 ), although the difference was not significant because of small numbers. Looking only at the 64 pairs in whom a CTLp assay was carried out, the OS and the EFS of the recipients of a CTLp-negative graft was 65 and 60%, respectively, compared with 33 and 33%, respectively, in cases with a CTLp-positive graft (see also Figure 3 ). Of the 80 fully matched donor-recipient combinations (group 1), 18 were DPB1-matched, 43 had one DPB1 mismatch and 16 had two DPB1 mismatches in GVHD direction. There was a trend towards a better actuarial OS and EFS of recipients with two DPB1 mismatches, although this did not reach significance. No effect was observed of degree of DPB1-matching on relapse of the disease at 2 years after transplantation for the children grafted for a malignant disease (data not shown).
The rate of occurrence of other patient-or transplantrelated variables in the study population (n ¼ 126) was as follows: 94 had a donor of X31 yrs of age, 59 donors were women, 53 recipients were X10 yrs of age, 53 recipients were CMV-positive and 40 couples were ABOincompatible.
Non-myeloablative or reduced intensity conditioning was applied exclusively in 19 out of 48 patients not suffering from a haematological malignancy. A full, that is, T-cell replete BM graft was given to 66 children, mostly suffering from severe aplastic anaemia, myelodysplastic syndromes, juvenile myelomonocytic leukemia, Ph þ CML and AML, according to the donor selection criteria and transplant policy of our centre (see above). Table 3 summarizes, in relation to the original diagnosis of the patients, the findings regarding the failure of engraftment, GVHD, relapse of the disease and death related to disease or transplantation, including the cause of TRM. In total 104 of the 122 evaluable children (85%) engrafted successfully after the first UD-BMT. Of the 18 failures, 16 were non-engraftments or rejections, and two were very early relapses. A total of 12 graft failures occurred in children treated for inherited diseases or severe aplastic anaemia (12 out of 46, 26%). Of these 12, six occurred after reduced intensity conditioning and six after myeloablative conditioning. Children with a malignant disease had about a fivefold smaller risk of graft failure (4 out of 76, 5%) (hazard ratio ¼ 0.22, CI ¼ 0.07-0.7, P ¼ 0.011). Risk of graft failure was not correlated with the degree of matching between donor and recipient. In total, 11 of the 16 patients grafted for severe aplastic anaemia or Fanconi were hypertransfused before BMT, that is, received 420 erythrocyte or thrombocyte transfusions before BMT. Graft failure occurred in 5 of these 11, as compared with two of five other cases (NS). Other variables were not of importance for engraftment.
Only 9 of 120 evaluable cases (7.5%) got X grade II acute GVHD, in every case after a T-cell replete graft by malignant and non-malignant diseases. Overall survival for all patients (n ¼ 126) was 59% at 2 years. Patients with a malignant disease (n ¼ 78) had a 2-year survival of 57%, whereas patients with a non-malignant disease (n ¼ 48) had a 2-year survival of 63% (log-rank ¼ 0.04, P ¼ 0.9).
(log-rank 8.64, P ¼ 0.003 in favour of TCD). The severity was grade II Â 6, grade III Â 2 and grade IV Â 1. The latter patient died because of adenovirus infection and liver failure, although GVHD was regressing. Besides that, 17 recipients got grade I acute GVHD. For the occurrence of moderate-to-severe acute GVHD, that is, X grade II, there was no relation with matching or mismatching for HLA-A, -B, -C, -DRB1 and -DQB1: seven of the nine cases were observed in fully matched recipients (group 1). Of these seven, three had a DPB1 mismatch with their donor in GVHD direction. A total of 14 chronic GVHD cases were diagnosed (out of 98 evaluable cases, 14%), four with limited and 10 with extensive disease; four of them developed de novo chronic GVHD. Except for preceding acute GVHD, no transplant-related variable was of importance for the occurrence of chronic GVHD. In the 68 evaluable cases, grafted for a haematological malignancy, there was a trend to more chronic GVHD in two DPB1-mismatched combinations (3 out of 14) than in other combinations (no or one DPB1 mismatch) (6 out of 54)(NS). Cumulative chance of relapse in patients, grafted for a haematological malignancy (n ¼ 78, see Table 1 ), was three times higher, that is, 28 vs 10%, in cases with an increased relapse risk post-BMT (n ¼ 40) than in cases with a standard relapse risk post-BMT (n ¼ 38) (P ¼ 0.055).
Infection was a major cause of TRM after the first BMT, that is, in 14 of the 23 cases. Except for two cases with a sepsis without documented bacteraemia, all lethal infections were caused either by fungi (n ¼ 3) or by viruses (n ¼ 9) already latently present before SCT in the host. All lethal Epstein-Barr virus infections occurred after TCD-BMT.
The univariate analysis of the effect of categorical transplant-related variables on OS and EFS gave a worse OS of patients older than 10 years (hazard ratio ¼ 1.85, CI ¼ 1.02-3.36, P ¼ 0.041) and a worse EFS of male recipients of a female graft (hazard ratio ¼ 1.7, CI ¼ 0.96-3.03, P ¼ 0.066). Patients with a donor who was identical for HLA-class I Ags and not for class II Ags (group 2 of Table 2 ) had a better EFS than other matching combinations (hazard ratio ¼ 0.165, CI ¼ 0.02-1.2, P ¼ 0.076). No positive or negative effect by any of the other discrete variables was found. Neither the diagnosis nor the period of BMT, that is, early (1988-1998) vs late (1999-2004) had any effect on OS and EFS of the graft recipients. Table 4 shows the results of a multivariate analysis of all studied parameters on OS and EFS. Again, recipients of HLAmatching group 2 had a better OS and EFS, though not significant because of small numbers; the inferior OS of patients older than 10 years was confirmed, whereas the adverse effect of a female graft for the outcome in a male recipient was only marginal.
Discussion
This retrospective study on the outcome of BMT from UD encompasses all children, consecutively grafted in our SCTCentre over a period of almost 17 years. The paediatric patient population is heterogeneous, with a mixture of different diagnoses (see Table 1 ), characteristic of a paediatric SCT-Centre. [43] [44] [45] [46] [47] [48] A total of 87% of the patients were of Northwest European origin, and 13% were of other ethnicities. During the period of the study, HLA-typing techniques changed from serological tests to high-resolu- tion DNA typing, but MLC tests were carried out during the entire period, and CTLp tests from 1992 onwards.
From all recipients, grafted in the earlier period and typed only by serology and MLC before BMT, frozen cells could be retrieved and used for DNA typing for the purpose of this evaluation, except in seven cases. Moreover, no CTLp assays were carried out in these donor-recipients couples, they were excluded from evaluation. GVHD prophylaxis was mainly (that is, 114 out of 124) by MTX-CsA or CsA alone, according to the operative EBMT or ESID protocols, and TCD of the graft, either by physical means or by Campath-1G in the bag, resulted in 2-3 log TCD of the graft; vigorous TCD by CliniMACS was only used twice.
Other important transplantation variables, such as donor selection criteria, conditioning and the use of protective isolation combined with total suppression of the facultative anaerobic gut microflora, did not change during the entire period. Microbiological surveillance techniques for infections with bacteria, yeasts and fungi were similar over time; as to early detection of viral reactivations, molecular techniques to quantitate viral DNA in blood 49 were introduced progressively in recent years. Despite these inevitable drawbacks of a retrospective study, some conclusions with respect to the effect of the degree of HLA-matching and discrete patient-and transplant-related variables on SCT-outcome can be drawn.
Overall outcome of UD-BMT in our paediatric population was satisfactory. Despite the diagnosis of sepsis in two cases, causative bacteria could not be documented; all lethal infections were caused by endogenous microorganisms, that is, fungi and viruses already latently present in the recipient before BMT; this illustrates the effect of strict protective isolation. Epstein-Barr virus-B-cell lymphoproliferative syndrome (BLPS) was only seen in recipients of a TCD-BMT, and occurred before the era of standard rituximab (anti-CD20) treatment. 50 Also, the frequency of moderate-to-severe (X grade II) acute GVHD was low, showing the beneficial effect of suppressing the gastrointestinal microflora, including the anaerobic bacteria, on this complication, as shown earlier by us 20 and by others. 51 As to the question of how to further improve the results of UD-BMT by modifying the strategy for donor selection, the following can be learned from the data of this study. In our relatively small group of patients, we were unable to show a significant adverse effect of the degree of HLAmatching on the outcome. This is in contrast with the results of a recent CIBMTR report on 3857 patients, receiving an UD-BMT, 52 which showed that a single mismatch in any of the major MHC loci (HLA-A, -B, -C and -DRB1) had an almost equal adverse effect on OS/ DFS. If anything may be concluded, it is the superiority of a donor with a class II mismatch in combination with a high-resolution matching for class I alleles.
Evaluation of the outcome of an other large group of BMT recipients, registered by the Japan Marrow Donor Program, gives data more in accordance with our findings: HLA-A and/or -B allele mismatch had a clear adverse effect on OS, whereas HLA-C or HLA-class II did not. 53 Also Leung et al. 44 showed in their retrospective analysis of 129 children, receiving an UD-BMT, that an HLA-A (and to a lesser extend HLA-B) mismatch clearly had an adverse effect on the frequency of X II acute GVHD and on OS, whereas HLA-DR mismatch had no such effect. This unequal relevance of HLA-Ags/allele mismatches is further corroborated by the results of the CTLp assay, an in vitro assay for the T-cellular reactivity from donor cells to recipient cells (in the GVHD direction), which in our study showed a superior OS and EFS for the CTLp-negative in comparison with -positive combinations (see Figure 3) . Under the specific conditions of our UD-BMT setting, HLA-class II mismatches in combination with either a negative CTLp assay or an HLA-class I high-resolution match maybe accepted as permissible mismatches. An alternative for a negative CTLp assay, a technically demanding test, might be a high-resolution match for HLA-A, -B and -DRB1 in combination with a highly diverged HLA-C mismatch. 54 We could not confirm an adverse effect on acute GVHD and OS, or a beneficial effect on relapse rate of malignancies, of HLA-C or HLA-DPB1 mismatches between donor and recipient, as found by others, [55] [56] [57] [58] [59] [60] [61] probably because of small numbers. From the other discrete patient-and transplant-related variables, possibly affecting the outcome of UD-BMT (see Table 4 ), two variables, that is, a (an adult) female donor for a male patient and an age above 10 yrs of the recipient showed a trend of a significant adverse effect, respectively, on the survival of patients, confirming the findings of others. [28] [29] 62 In conclusion, first, when no matched sibling donor is available for BMT, an UD-BMT is feasible in the majority of patients and gives a long-term survival of about 60%. Finding a suitable BMDW-registered stem cell donor, nowadays, in a reasonable time span of 3-4 months is feasible for up to 85% of children of Northwest European origin. 7, 63 The success rate of finding such a donor is smaller for patients of Southern and Eastern European or non-European origin; though there is improvement, 43, 62, 63 a simultaneous search in cord blood banks is advised for those patients. 64 Accepting HLA-class II mismatch could even increase the percentage of potentially suitable UD's. In case of choice a male donor for a male recipient might be the preferable combination. UD-BMT should not be deferred and used as last resort in children with a haematological malignancy, rather it should be carried out at an early stage in high-risk cases. Second, under conditions of protective isolation, close microbiological surveillance and suppression of the facultative and strict anaerobic gut microflora, as used in this study, transplantrelated morbidity and mortality were low, and relapse rate of malignancies and survival were in the order of magnitude of those in matched sibling donor SCT's. Paying special attention at pre-emptive treatment of some specific opportunistic microorganisms, for example, Aspergillus sp. and some DNA-viruses (CMV, Epstein-Barr virus and adenovirus) may even further improve the results of UD-BMT.
